Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 4Small Cell Lung Carcinoma 2Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Malignant Solid Tumor 1Glioblastoma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 14Bevacizumab 11Erlotinib Hydrochloride 5Radiotherapy 4Carboplatin 4Magnetic Resonance Spectroscopy 3Irinotecan 3Immunoglobulin G 3Disulfides 3temsirolimus 2poly ICLC 2palbociclib 2etoposide phosphate 2antineoplaston AS 2-1 2antineoplaston A10 2Vincristine 2Sunitinib 2Sirolimus 2Everolimus 2Dasatinib 22-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 2veliparib 1varlilumab 1vandetanib 1trebananib 1trametinib 1terameprocol 1tandutinib 1selinexor 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Oligodendroglioma × etirinotecan pegol × Clear all
NCT01663012 2016-02-24

Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma

Stanford University

Phase 2 Completed
20 enrolled 10 charts
CNS

Astrocytoma, Glioblastoma, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡